CAKI-1

CAKI-1 (亦稱ATCC HTB-46) 是人類腎透明細胞癌皮膚轉移細胞系[1]，最初是分離自一名49歲的白人男性腎癌患者[2]。

特徴

Caki-1細胞中高表達的基因345個，而低表達的基因則有217個[3]。CAKI-1細胞的染色體倍性在三倍體範圍內，並且不存在Y染色體，因為Y染色體的缺失在雄性腫瘤細胞系中並不罕見。除染色體N9和N19以外，所有的染色體都擁有2或3個拷貝。Caki-1細胞有許多微絨毛、發育充分的高爾基體與內質網、細小的線粒體及少許微絲，目前並沒有在細胞內發現任何病毒顆粒。

科研用途

有學者提議將其作為近端腎小管上皮組織的模型，因為細胞在培養過程中，可以形成具有功能性及高度分化的腎組織形態、生理及生化特徵的極化層 (polarized layer) [4]。有研究指出Caki-1是轉移性腎亮細胞癌的常用模型，當其攜帶着野生型vhl抑癌基因時，它就能在无胸腺裸鼠中產生清晰可見的腫瘤[5]。這些細胞高表達血管內皮生長因子[6]（特別是在氧氣濃度低的情況[7]）的特徵就是腎亮細胞癌的標誌。

參考資料

Breuksch, I; Prosinger, F; Baehr, F; Engelhardt, FP; Bauer, HK; Thüroff, JW; Heimes, AS; Hasenburg, A; Prawitt, D; Brenner, W. . Oncotarget. 2017-12-08, 8 (64): 107530–107542 [2019-12-09]. PMID 29296184. doi:10.18632/oncotarget.22501.
Fogh, J; Wright, WC; Loveless, JD. . Journal of the National Cancer Institute. 1977-02, 58 (2): 209–14 [2019-12-09]. PMID 833871. doi:10.1093/jnci/58.2.209.
Hehuan Zhu. . Chinese Journal of Cell and Stem Cell. 2018-11, 8 (2): 80–7 [2019-12-09]. doi:10.3877//cma.j.issn.2095-1221.2018.02.003. （原始内容存档于2019-12-09）.
Glube, N; Giessl, A; Wolfrum, U; Langguth, P. . Nephron. Experimental nephrology. 2007, 107 (2): e47–56 [2019-12-09]. PMID 17804913. doi:10.1159/000107804.
Lichner, Z; Saleh, C; Subramaniam, V; Seivwright, A; Prud'homme, GJ; Yousef, GM. . Oncotarget. 2015-03-20, 6 (8): 5567–81 [2019-12-09]. PMID 25011053. doi:10.18632/oncotarget.1901.
Liu, YH; Lin, CY; Lin, WC; Tang, SW; Lai, MK; Lin, JY. . Journal of immunology (Baltimore, Md. : 1950). 2008-11-01, 181 (9): 6584–94 [2019-12-09]. PMID 18941249. doi:10.4049/jimmunol.181.9.6584.
Miyake, M; Goodison, S; Lawton, A; Zhang, G; Gomes-Giacoia, E; Rosser, CJ. . Journal of hematology & oncology. 2013-09-03, 6: 65 [2019-12-09]. PMID 24004818. doi:10.1186/1756-8722-6-65.

外部連結

Cellosaurus entry for CAKI-1（页面存档备份，存于）

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Breuksch, I; Prosinger, F; Baehr, F; Engelhardt, FP; Bauer, HK; Thüroff, JW; Heimes, AS; Hasenburg, A; Prawitt, D; Brenner, W. . Oncotarget. 2017-12-08, 8 (64): 107530–107542 [2019-12-09]. PMID 29296184. doi:10.18632/oncotarget.22501.

[2] Fogh, J; Wright, WC; Loveless, JD. . Journal of the National Cancer Institute. 1977-02, 58 (2): 209–14 [2019-12-09]. PMID 833871. doi:10.1093/jnci/58.2.209.

[3] Hehuan Zhu. . Chinese Journal of Cell and Stem Cell. 2018-11, 8 (2): 80–7 [2019-12-09]. doi:10.3877//cma.j.issn.2095-1221.2018.02.003. （原始内容存档于2019-12-09）.

[4] Glube, N; Giessl, A; Wolfrum, U; Langguth, P. . Nephron. Experimental nephrology. 2007, 107 (2): e47–56 [2019-12-09]. PMID 17804913. doi:10.1159/000107804.

[5] Lichner, Z; Saleh, C; Subramaniam, V; Seivwright, A; Prud'homme, GJ; Yousef, GM. . Oncotarget. 2015-03-20, 6 (8): 5567–81 [2019-12-09]. PMID 25011053. doi:10.18632/oncotarget.1901.

[6] Liu, YH; Lin, CY; Lin, WC; Tang, SW; Lai, MK; Lin, JY. . Journal of immunology (Baltimore, Md. : 1950). 2008-11-01, 181 (9): 6584–94 [2019-12-09]. PMID 18941249. doi:10.4049/jimmunol.181.9.6584.

[7] Miyake, M; Goodison, S; Lawton, A; Zhang, G; Gomes-Giacoia, E; Rosser, CJ. . Journal of hematology & oncology. 2013-09-03, 6: 65 [2019-12-09]. PMID 24004818. doi:10.1186/1756-8722-6-65.